bioMérieux (OTCMKTS:BMXMF) Upgraded by Zacks Investment Research to Hold

bioMérieux (OTCMKTS:BMXMFGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “bioMérieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioMérieux S.A. is based in Marcy L Etoile, France. “

Shares of bioMérieux stock traded up $3.94 on Tuesday, reaching $95.61. 72 shares of the company were exchanged, compared to its average volume of 289. bioMérieux has a one year low of $87.13 and a one year high of $148.50. The company has a current ratio of 2.31, a quick ratio of 1.65 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average of $100.50 and a 200 day moving average of $115.19.

About bioMérieux (Get Rating)

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors.

Featured Articles

Get a free copy of the Zacks research report on bioMérieux (BMXMF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for bioMérieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMérieux and related companies with MarketBeat.com's FREE daily email newsletter.